• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
MeTA country guidance note
 

MeTA country guidance note

on

  • 1,905 views

Presentation by Emma Back, MeTA consultant during the MeTA countries sharing meeting, London, December 2009.

Presentation by Emma Back, MeTA consultant during the MeTA countries sharing meeting, London, December 2009.

Statistics

Views

Total Views
1,905
Views on SlideShare
1,903
Embed Views
2

Actions

Likes
0
Downloads
7
Comments
0

1 Embed 2

http://www.slideshare.net 2

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    MeTA country guidance note MeTA country guidance note Presentation Transcript

    • Emma Back MeTA Consultant MeTA country guidance note ‘Moving towards medicines data transparency, joint analysis and evidence-based policies to improve access to medicines’ 8 December 2009
    • Purpose of the guidance note
      • To provide advice and guidance to MeTA pilot countries – specifically national Secretariats and multi-stakeholder groups – as they take steps towards establishing a process of routine disclosure of key medicines data.
      • To provide some tools and examples to aid this process, share case studies and lessons from different countries, and identify potential sources of TA.
      • Broader purpose:
      • The note will help to ensure standardization of reporting across MeTA countries, which will in turn aid comparison, monitoring and evaluation .
    • Proposed content
      • Recap of MeTA pilot phase goals and principles
      • Purpose of guidance note in this context
      • Phased approach towards increasing transparency, [accountability,] and evidence-based policy and practice; an ongoing cycle:
      • Diagnosis
      • Setting parameters; agreeing reporting format; agreeing process
      • Data collection / submission; data assessment
      • Multi-stakeholder discussion of the data
      • Data use - including for comms, advocacy and policy development
      • Reporting and monitoring
      • Using the phased approach in practice
      • Securing additional support
    • Questions for you
      • Does the step-wise approach make sense?
      • Will the proposed format of the guidance note give you what you need?
      • What else would you like to see in the note? What do you need most guidance on? TA priorities?
      • Do you have any case studies or lessons you would like to share through the guidance note?
      • Any data collection / disclosure / reporting formats?